Orrick Advises 23andMe on $250 Million Financing Round

September.13.2017

Orrick has advised 23andMe, the leading consumer genetics and research company, on its $250 million Series F financing round. Led by new investor Sequoia Capital, additional investors included Euclidean Capital, Altimeter Capital, the Wallenberg Foundation, Fidelity Management & Research Company and Casdin Capital.

The financing will enable 23andMe to accelerate customer growth, continue funding its expanding therapeutics group and invest in its crowdsourced genetic research platform. This financing brings the total capital raised by 23andMe to $491 million.

Orrick has represented 23andMe since 2008, advising the company on numerous matters across a range of practice groups, including its four latest financing rounds. The Orrick team was led by partner Karen Dempsey and included partner Amanda Galton and associates Brandon SandersAhalya Hildreth and Andrew Miller.